ライフサイエンスコーパス: fibroproliferative

1 can ameliorate both the direct and indirect fibroproliferative actions of TGF-beta.

2 ich critically ill surgical patients develop fibroproliferative acute respiratory distress syndrome.

3 Asbestos is a carcinogen and fibroproliferative agent in lung that may cause cell sig

4 Fibrosis, microvascular fibroproliferative alterations, and autoantibody product

5 mbating chronic rejection by inhibiting both fibroproliferative and alloimmune responses.

6 Furthermore, the findings suggest that fibroproliferative and inflammatory lesions are independ

7 ung inflammation and the development of late fibroproliferative ARDS, or if it is predictive of a ben

8 ne 125 mg i.v. every 6 hrs was initiated for fibroproliferative ARDS.

9 ecular mechanisms governing inflammatory and fibroproliferative aspects of the disorder are not clear

10 played histological characteristics of bone, fibroproliferative cells, blood vessels, and adipose tis

11 poxic pulmonary hypertension includes marked fibroproliferative changes in the pulmonary artery (PA)

12 d 11 days after symptom onset, had pulmonary fibroproliferative changes.

13 lmonary lymphatics is a critical mediator of fibroproliferative changes.

14 0.001), but they also developed obstructive fibroproliferative coronary artery lesions much earlier

15 Keloid disease is a recurrent fibroproliferative cutaneous tumor of unknown pathogenes

16 of connective tissue growth factor (CTGF), a fibroproliferative cytokine, by transforming growth fact

17 KD is a common fibroproliferative dermal lesion with an ill-defined tre

18 Arthrofibrosis is a fibroproliferative disease characterised by excessive de

19 This fibroproliferative disease may be promoted by overproduc

20 fibrosis (IPF) is an insidious inflammatory fibroproliferative disease whose cause and course before

21 ls are known to be the key effector cells of fibroproliferative disease, but the specific matrix sign

22 ession at sites of lung injury in developing fibroproliferative disease.

23 pathic pulmonary fibrosis (IPF) is a lethal, fibroproliferative disease.

24 Chronic fibroproliferative diseases account for approximately 45

25 ic diseases are to discuss some of the major fibroproliferative diseases and to identify the common a

26 Fibroproliferative diseases are driven by dysregulated t

27 Unfortunately, fibroproliferative diseases remain intractable to curren

28 are strongly implicated in the formation of fibroproliferative diseases such as proliferative vitreo

29 Fibroproliferative diseases, including the pulmonary fib

30 tants and are involved in other inflammation/fibroproliferative diseases, we hypothesized that the ex

31 a critical event in the genesis of pulmonary fibroproliferative diseases.

32 ted response has been implicated in multiple fibroproliferative diseases.

33 L-1 and has been associated with a number of fibroproliferative diseases.

34 s to the development and progression of this fibroproliferative disorder and identified TNF as a ther

35 ibrosis (IPF) is a progressive and incurable fibroproliferative disorder characterized by unrelenting

36 It is an increasingly common and disabling fibroproliferative disorder of the palmar fascia, which

37 ic pulmonary fibrosis (IPF) is a progressive fibroproliferative disorder refractory to current pharma

38 harmacological target for immunosuppression, fibroproliferative disorders, atherosclerosis, and strok

39 e receptor CXCR3 is functionally involved in fibroproliferative disorders, including liver fibrosis.

40 icellular protein that plays a major role in fibroproliferative disorders.

41 pathogenesis of pulmonary fibrosis and other fibroproliferative disorders.

42 ion of extracellular matrix observed in many fibroproliferative disorders.

43 ons is an effective therapeutic strategy for fibroproliferative disorders.

44 plays a central role in the pathogenesis of fibroproliferative disorders.

45 itors as potential therapy for patients with fibroproliferative disorders.

46 E prostanoid (EP) receptors in mediating the fibroproliferative effects of IL-1beta in ALI.

47 d serum tryptase were more likely to develop fibroproliferative end organ damage, and 3 of 9 died wit

48 sion subsets described previously, including fibroproliferative, inflammatory, and normal-like groups

49 mprovement were classified as normal-like or fibroproliferative intrinsic subsets.

50 ling that occurs during the development of a fibroproliferative lesion and could facilitate biologica

51 reased levels in cells derived from an early fibroproliferative lesion in a patient with fibrodysplas

52 Keloid disease (KD) is a fibroproliferative lesion of unknown etiopathogenesis th

53 a knocked out (TNF-alphaRKO) fail to develop fibroproliferative lesions after asbestos exposure.

54 These fibroproliferative lesions lead to neointimal thickening

55 ed at 8 to 12 weeks and demonstrated intimal fibroproliferative lesions with a mild parenchymal monon

56 is associated with accumulation of fibrin in fibroproliferative lesions.

57 s in fibrin gels, an in vitro model of early fibroproliferative lesions.

58 signaling protected the mice from developing fibroproliferative lesions.

59 kines are produced during the development of fibroproliferative lung disease.

60 ) is a prevalent, progressive, and incurable fibroproliferative lung disease.

61 Despite the importance of fibroproliferative lung disorders, no safe and effective

62 re upregulated prior to the development of a fibroproliferative lung lesion, and thus may play a cent

63 s sarcoma-associated herpesvirus (KSHV) in a fibroproliferative malignancy of macaques that has simil

64 roperitoneal fibromatosis (RF) is a vascular fibroproliferative neoplasm which has many morphological

65 insic gene expression subsets (inflammatory, fibroproliferative, normal-like, and limited) are observ

66 ration, cartilage erosion, bone erosion, and fibroproliferative pannus) or frozen, cryosectioned, and

67 The fibroproliferative phase of acute respiratory distress s

68 CXC chemokines have an important role in the fibroproliferative phase of ARDS via the regulation of a

69 int to a newly described role for HGF in the fibroproliferative phase of RA-associated synovitis.

70 suppresses TGF-beta1-induced myofibroblast (fibroproliferative) phenotypic genes, for example, alpha

71 they are not necessary for the formation of fibroproliferative plaques.

72 chiolitis obliterans syndrome is caused by a fibroproliferative process in lung allografts resulting

73 echanistic research has focused on the local fibroproliferative process in the lung.

74 (IH) formation that induces inflammatory and fibroproliferative processes and ultimately restenosis.

75 EGFR activation is associated with fibroproliferative processes in human lung disease and a

76 rombin may be important for inflammatory and fibroproliferative processes in wound healing.

77 ute radiation toxicity and in sustaining the fibroproliferative processes that lead to chronic radiat

78 Angiogenesis and vascular remodeling support fibroproliferative processes; however, no study has addr

79 Concordantly, abrogation of QKI attenuated fibroproliferative properties of VSMCs, while potently i

80 pathic pulmonary fibrosis (IPF) is a chronic fibroproliferative pulmonary disorder for which there ar

81 The fibroproliferative reaction to acute lung injury may lim

82 Fibroproliferative remodeling in smooth muscle-rich holl

83 mation results from chronic inflammation and fibroproliferative remodeling in the vascular wall.

84 g by ameliorating cell death and stimulating fibroproliferative repair.

85 One of these involves the fibroproliferative response after acute lung injury, whi

86 Mice deficient in PTEN showed a prolonged fibroproliferative response after tissue injury, and imm

87 U/kg), Stat1-/- mice exhibited a more severe fibroproliferative response and significantly elevated t

88 TGF-alpha is associated with a marker of the fibroproliferative response in sustained ARDS.

89 The excessive fibroproliferative response leading to luminal narrowing

90 atent TGF-beta1, resulting in promotion of a fibroproliferative response over an inflammatory respons

91 tion and that they likely play a role in the fibroproliferative response seen in human acute lung inj

92 ress syndrome (ARDS) frequently results in a fibroproliferative response that precludes effective alv

93 The fibroproliferative response to acute lung injury (ALI) r

94 Such mechanisms may drive the fibroproliferative response to ALI.

95 ch Hh-responsive cells accumulate during the fibroproliferative response to chronic cholestatic liver

96 RNA and protein expression and the degree of fibroproliferative response to inhaled asbestos fibers a

97 no soluble TNF-alpha display an accentuated fibroproliferative response to low shear stress (P:<0.05

98 Although the fibroproliferative response to lung injury occurs with a

99 and smooth muscle cells, and it reduces the fibroproliferative response to vascular injury.

100 overexpression on liver angiogenesis and the fibroproliferative response using a Tet-inducible bitran

101 cates medial calcification, the inflammatory-fibroproliferative response, and inflammation-mediated e

102 Matriptase-induced fibroproliferative responses and the receptor involved w

103 ies to reduce lung levels of MMP-8 may limit fibroproliferative responses to injury in the human lung

104 n in QKI activity can ameliorate pathogenic, fibroproliferative responses to vascular injury.

105 Thus, we explored the role of CD69 in fibroproliferative responses using a mouse model of peri

106 TLR3-mediated cytokine, type 1 IFN, and fibroproliferative responses were examined in TLR3 wild-

107 ulted in defective cytokine, type I IFN, and fibroproliferative responses.

108 Fibroproliferative scars are an important clinical probl

109 fibrosis are likely to benefit those with a fibroproliferative signature.

110 ve connections between the inflammatory- and fibroproliferative-specific genes.

111 n the inflammatory subset do not move to the fibroproliferative subset, and vice versa.

112 fective therapeutic agents for SSc and other fibroproliferative vasculopathies in which EndoMT plays

113 EndoMT may play a role in the development of fibroproliferative vasculopathies.

114 olved in the pathogenesis of the progressive fibroproliferative vasculopathy which is a hallmark of s